Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL28322635 | 0.94 | RAB9A (0.54) | FABP4RAB9ANPC1POLBCASP3 | |
| SCHEMBL9327652 | 0.90 | CTNNB1 (0.55) | FABP4RAB9ANPC1POLBCASP3 | |
| SCHEMBL1669323 | 0.87 | AKR1B1 (0.49) | FABP4RAB9ANPC1POLBAKR1B1 | |
| SCHEMBL2777357 | 0.87 | RAB9A (0.52) | FABP4RAB9ANPC1POLBCASP3 | |
| SCHEMBL1462799 | 0.85 | RAB9A (0.51) | FABP4RAB9ANPC1POLBCASP3 | |
| SCHEMBL10371320 | 0.85 | RAB9A (0.51) | FABP4RAB9ANPC1POLBCASP3 | |
| SCHEMBL4678364 | 0.85 | RAB9A (0.52) | FABP4RAB9ANPC1POLBCASP3 | |
| SCHEMBL8861724 | 0.84 | RAB9A (0.51) | FABP4RAB9ANPC1POLBCASP3 | |
| SCHEMBL81136 | 0.84 | FABP4 (0.58) | FABP4RAB9ANPC1POLBCASP3 | |
| SCHEMBL8938549 | 0.84 | AKR1B1 (0.44) | FABP4RAB9ANPC1POLBCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107721954-B | Novel preparation method of darifenacin intermediate 2, 3-dihydro-5-benzofuran acetic acid | 内蒙古京东药业有限公司 | 2020-02-14 | — | — | CN | claimed |
| CN-107721955-B | Darifenacin intermediate 2, the novel preparation method of 3- dihydro -5- benzofuranacetic acid | 内蒙古京东药业有限公司 | 2019-10-11 | — | — | CN | claimed |
| CN-107721955-A | The novel preparation method of the benzofuranacetic acid of 2,3 dihydro of darifenacin intermediate 5 | 内蒙古京东药业有限公司 | 2018-02-23 | — | — | CN | claimed |
| CN-107721954-A | The novel preparation method of the benzofuranacetic acid of 2,3 dihydro of darifenacin intermediate 5 | 内蒙古京东药业有限公司 | 2018-02-23 | — | — | CN | claimed |
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-10-30 | — | — | US | claimed |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-30 | — | — | US | claimed |
| EP-0794183-B1 | (2,3-Dihydro-5-benzofuranyl)-acetonitrile | BAYER AG (DE) | 2000-06-14 | — | — | EP | claimed |
| US-5693831-A | (2,3-dihydro-5-benzofuranyl)-acetonitrile | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-02 | — | — | US | claimed |
| EP-0794183-A1 | (2,3-Dihydro-5-benzofuranyl)-acetonitrile | BAYER AG (DE) | 1997-09-10 | — | — | EP | claimed |
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| CN-119191962-A | Preparation method of a-deuterated carboxylic acid derivative compound | 常州大学 | 2024-12-27 | — | — | CN | disclosed |
| US-20240409550-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4464317-A2 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | Sumitomo Pharma America, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3494119-B1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA INC (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-0350309-A1 | Piperidine derivatives | Pfizer Limited (GB) | 1990-01-10 | — | — | EP | disclosed |
| US-4816473-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS | SYNTEX (U.S.A.) INC. (US) | 1989-03-28 | — | — | US | disclosed |
| US-4780480-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1988-10-25 | — | — | US | disclosed |
| EP-0132130-A2 | Aroyl benzofuran and benzothiophene acetic and propionic acids processes for their production and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1985-01-23 | — | — | EP | disclosed |
| US-4229575-A | ANTIBIOTICS | RICHARDSON-MERRELL INC. (US) | 1980-10-21 | — | — | US | disclosed |
| US-4138397-A | BACTERICIDES | RICHARDSON-MERRELL INC. (US) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409550-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | FABP4 3538/4885RAB9A 1501/4885NPC1 166/4885 |
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ADH1C, HTR6, CNR1 | FABP4 3466/4885RAB9A 1637/4885NPC1 137/4885 |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | CHRNE, CHRM3, CHRM2 | FABP4 3704/4885RAB9A 3273/4885NPC1 4762/4885 |
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | FABP4 4478/4885RAB9A 956/4885NPC1 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.